<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2981">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04569227</url>
  </required_header>
  <id_info>
    <org_study_id>EC-18-204</org_study_id>
    <nct_id>NCT04569227</nct_id>
  </id_info>
  <brief_title>Prevention of COVID-19 Infection to Severe Pneumonia or ARDS</brief_title>
  <official_title>Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of EC-18 in Preventing the Progression of COVID-19 Infection to Severe Pneumonia or ARDS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Enzychem Lifesciences Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Enzychem Lifesciences Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A trial of EC-18 in patients with mild/moderate pneumonia due to COVID-19&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 16, 2020</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients alive and free of respiratory failure through at Day 28</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Probability of progression of mild pneumonia patients to severe pneumonia or ARDS within 28 days</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of all-cause mortality</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory failure defined based on resource utilization requiring at least 1 of the following:</measure>
    <time_frame>28 days</time_frame>
    <description>Endotracheal intubation and mechanical ventilation&#xD;
Oxygen delivered by high-flow nasal cannula (heated, humidified, oxygen delivered via reinforced nasal cannula at flow rates &gt; 20L/min with a fraction of delivered oxygen ≥ 0.5)&#xD;
Non-invasive positive pressure ventilation&#xD;
Extracorporeal membrane oxygenation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients alive and free of invasive mechanical ventilation at a pre-specified timepoint</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients alive and discharged from the hospital at a pre-specified timepoint</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lengths of ICU stay</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lengths of alive and respiratory failure-free days</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with objective measures of improvement (returning to room air) at time points (days 7, 14, and 28)</measure>
    <time_frame>7, 14, and 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Confirmation of changes in subject's subjective clinical symptoms (e.g., patient questionnaire)</measure>
    <time_frame>28 days</time_frame>
    <description>o Check for changes in symptoms on a daily basis for 28 days compared to the baseline at day 1</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Covid19 Pneumonia</condition>
  <arm_group>
    <arm_group_label>Active EC-18</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EC-18</intervention_name>
    <description>2000 mg PO daily</description>
    <arm_group_label>Active EC-18</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>PO daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must meet all of the following criteria:&#xD;
&#xD;
               1. Male or female ≥18 years old&#xD;
&#xD;
               2. Subjects with confirmed diagnoses of pneumonia caused by COVID-19 from:&#xD;
&#xD;
                    -  RT-PCR or Abbott ID Now COVID-19 test&#xD;
&#xD;
                    -  Chest X-ray or computed tomography (CT) scan (findings of the increased&#xD;
                       opacity on a chest X-ray, ground-glass opacity indicative of pneumonia on&#xD;
                       CT, opinion on consolidation, etc.)&#xD;
&#xD;
               3. Those who can tolerate oral administration&#xD;
&#xD;
               4. Those who do not need oxygen therapy or only need low-flow oxygen (at least&#xD;
                  4L/min) but not requiring high-flow oxygen (higher than 4-6L/min) or&#xD;
                  non-invasive/invasive ventilation primarily according to the WHO guidance&#xD;
&#xD;
               5. Those who are planned to be hospitalized or who are just hospitalized&#xD;
&#xD;
               6. Those who have been fully explained about this clinical study and have&#xD;
                  voluntarily agreed to participate in this clinical study by signing the informed&#xD;
                  consent form (ICF)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects cannot participate in this clinical study if they satisfy any of the&#xD;
             following criteria:&#xD;
&#xD;
               1. Those who are diagnosed with viral pneumonia caused by other than COVID-19 or&#xD;
                  bacterial pneumonia during the screening&#xD;
&#xD;
               2. Patients with severe pneumonia according to the WHO guidance&#xD;
&#xD;
                    -  Have fever or signs of respiratory infections and&#xD;
&#xD;
                    -  Satisfy any one of the following conditions: Respiratory rate &gt; 30&#xD;
                       breaths/min, severe respiratory distress, or room air oxygen saturation&#xD;
                       (SpO2) ≤ 93%&#xD;
&#xD;
               3. Patients with ARDS according to the WHO guidance&#xD;
&#xD;
               4. Those who have past medical histories described below:&#xD;
&#xD;
                    -  Those who have medical histories of human immunodeficiency virus (HIV),&#xD;
                       acquired immunodeficiency syndrome (AIDS), or hepatitis B or C viral&#xD;
                       infection&#xD;
&#xD;
                    -  Those who cannot have a CT test done due to allergy to contrast agents, etc.&#xD;
&#xD;
               5. Those who have comorbidities/symptoms described below:&#xD;
&#xD;
                    -  Those who have a history or evidence of another clinically significant&#xD;
                       condition that may pose risks to patient safety or interfere with the study&#xD;
                       procedures, assessments or completion as determined by the investigator&#xD;
&#xD;
                    -  Those who have moderate or severe renal impairment (eGFR &lt; 60 mL/min/1.73&#xD;
                       m2)&#xD;
&#xD;
                    -  Those who have moderate or severe hepatic impairment (Child-Pugh B or C,&#xD;
                       respectively)&#xD;
&#xD;
               6. Patients who are being treated with corticosteroids or other immunosuppressants&#xD;
                  for asthma or autoimmune diseases at the entry of study are excluded, because&#xD;
                  these drugs counteract the action mechanism of EC-18 (PLAG).&#xD;
&#xD;
               7. Those who have any abnormalities in laboratory tests described below:&#xD;
&#xD;
                    -  Clinically significant liver function abnormality (Satisfy any one or more&#xD;
                       of the following):&#xD;
&#xD;
                    -  Serum alanine aminotransferase (ALT) ≥ upper limit of normal (ULN) × 2.5&#xD;
&#xD;
                    -  Serum aspartate aminotransferase (AST) ≥ ULN × 2.5&#xD;
&#xD;
                    -  Serum total bilirubin ≥ ULN × 2.5&#xD;
&#xD;
               8. Patients with uncontrolled diabetes (HbA1c &gt; 7.0%)&#xD;
&#xD;
               9. Those who have hypersensitivity reactions to the IP and its components&#xD;
&#xD;
              10. Those who satisfy any of the descriptions below:&#xD;
&#xD;
                    -  Pregnant or breastfeeding female subjects&#xD;
&#xD;
                    -  Those who are planning on pregnancy or not using accepted contraception&#xD;
                       measures during the clinical study&#xD;
&#xD;
              11. Those who have participated in other clinical studies to receive IPs or apply&#xD;
                  investigational medical devices within 1 month from the time of obtaining the&#xD;
                  informed consent&#xD;
&#xD;
              12. Those who are considered to be ineligible to participate in the clinical study or&#xD;
                  have difficulty conducting this clinical study by the investigator&#xD;
&#xD;
              13. Those subjects with Hb &lt; lower limit of normal (LLN) for males and females&#xD;
&#xD;
              14. Those subjects with a platelet count &lt; LLN&#xD;
&#xD;
              15. Those subjects with a WBC &lt; LLN&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>John Choi, M.S.</last_name>
    <phone>201-676-3804</phone>
    <email>john.choi@enzychem.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ji Sun Park, Ph.D.</last_name>
    <phone>201-676-3807</phone>
    <email>jisun.park@enzychem.com</email>
  </overall_contact_backup>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 28, 2020</study_first_submitted>
  <study_first_submitted_qc>September 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 29, 2020</study_first_posted>
  <last_update_submitted>October 27, 2020</last_update_submitted>
  <last_update_submitted_qc>October 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

